Antimicrobial guidance update
This article was originally published in The Gray Sheet
Final guidance in FDA's pipeline on 510(k) submissions for devices or combination products that incorporate antimicrobial agents faces delays from a change in reviewers at the Office of Chief Council followed by the change in administration, the agency says (1"The Gray Sheet" Sept. 1, 2008, p. 6). Once finalized, FDA will begin new guidance on performance testing for the devices. "The majority of antimicrobials that we see on medical devices do elute off the device to a greater or lesser extent," said Sheila Murphey, infection control branch chief at FDA's device center. "We need to know how much; we need to know how much over a period of time; we need to know how much over a long period of time." Performance testing should be quantitative and support indications and conditions for use. It may include in vitro, in vivo and clinical testing, Murphey said
You may also be interested in...
Revisions to a draft guidance on 510(k) submissions for devices or combination products that incorporate antimicrobial agents are awaiting final sign-off at FDA, an agency staffer said last week
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.